Skip to main content

Theravance Biopharma, Inc.

TBPH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001583107

In the last 90 days, Theravance Biopharma, Inc. insiders filed 0 open-market purchases and 2 sales; 179 institutions reported holding it in 13F filings for Q2 2026, worth $817.5M in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Theravance Biopharma, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of TBPH: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders116121+5
Shares59.3M63.0M+3.67M (+6.2%)
Value$655.6M$602.5M−$53.1M (−8.1%)

New holders (19)

Institutions that held Theravance Biopharma, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to TBPH in Q1 2022
InstitutionSharesValue% of portfolio
Park West Asset Management LLC340,000$3.25M0.12%
First Pacific Advisors, LP139,774$1.34M0.02%
Putnam Investments LLC105,294$1.01M0.00%
Zazove Associates LLC59,599$570.0K0.05%
ExodusPoint Capital Management, LP53,850$515.0K0.01%
Gsa Capital Partners LLP49,456$473.0K0.06%
Walleye Capital LLC37,800$361.0K0.01%
Caption Management, LLC31,800$304.0K0.02%
Campbell & CO Investment Adviser LLC25,100$240.0K0.06%
SG3 Management, LLC24,800$237.0K0.07%
Franklin Resources Inc16,260$155.0K0.00%
Rafferty Asset Management, LLC12,707$121.0K0.00%
Diversified Trust Co12,122$116.0K0.00%
Allspring Global Investments Holdings, LLC11,144$106.0K0.00%
Two Sigma Advisers, LP10,700$102.0K0.00%
Principal Financial Group Inc10,525$101.0K0.00%
Amalgamated Financial Corp.9,556$91.0K0.00%
Lindbrook Capital, LLC593$6.00K0.00%
Elequin Capital LP16$00.00%

Sold out (14)

Institutions that held Theravance Biopharma, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.